Intermediate and Long-term Efficacy of Endovascular Treatment for TASC C&D Aortoiliac Occlusive Disease
NCT ID: NCT04966767
Last Updated: 2021-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
800 participants
OBSERVATIONAL
2021-08-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Validity of Extracorporeal Fenestration and in Situ Fenestration in Patients With Aortic Disease Involving the Left Subclavian Artery
NCT06256757
Thoracoabdominal Aortic Stent System for Endovascular Treatment of Thoracoabdominal Aortic Dissecting Aneurysm.
NCT05803564
Endovascular Graft Anchoring Different Regions of Ascending Aorta in the Treatment of Ascending Aortic Dissection
NCT04544579
Clinical Study for Evaluating the Safety and Efficacy of Total Endovascular Aortic Arch Repair
NCT03347812
Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells
NCT02919709
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to comply with all follow-up evaluations at the specified times
* Target lesion(s) located within the native infrarenal abdominal aorta and/or common iliac artery and/or external iliac artery
* Evidence of ≥ 50% stenosis, restenosis (from PTA or adjunct therapy, not including stents or stent grafts), or occlusion of target lesion(s), or arterial thrombosis underwent PMT or CDT
* Provides written informed consent
Exclusion Criteria
* Known hypersensitivity to contrast material that cannot be adequately pretreated
* Bleeding diathesis or coagulopathy, known hypercoagulable condition or refuses blood transfusion
* Female currently breastfeeding, pregnant, or of childbearing potential not using adequate contraceptive measures
* Life expectancy less than 24 months
* Current participation in an investigational drug or other device study
* Severe comorbid conditions
* Myocardial infarction or stroke within 3 months prior to enrollment
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
First Affiliated Hospital of Zhejiang University
OTHER
Chengdu University of Traditional Chinese Medicine
OTHER
Xuanwu Hospital, Beijing
OTHER
First People's Hospital of Hangzhou
OTHER
Qingdao Hiser Medical Group
OTHER
Second Affiliated Hospital of Soochow University
OTHER
Huashan Hospital
OTHER
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2021-426
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.